Abstract: Disclosed herein are methods in the field of cancer immunotherapy that involve the treatment of a subject having cancer by administering to the subject a toll-like receptor 7/8 (TLR7/8) agonist in combination with a long-acting IL-2R?-biased agonist and a programmed cell death protein 1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) axis inhibitor, and related compositions, dosage forms, and kits.

Abstract: Provided are multi-arm polymer conjugates of Toll-Like Receptor (“TLR”) agonists such as TLR 7/8 agonists, as well as related compositions, and methods of making and using such conjugates. Exemplary conjugates are encompassed by Formula I: RQ-POLY-Xr-TLR7/8 AG)q??Formula I or a pharmaceutically acceptable salt form thereof, where R, taken together with each Q, is a residue of a polyol, polythiol, or polyamine bearing from 3 to about 50 hydroxyl, thiol, or amino groups; each Q is a linker selected from oxygen, sulfur and —NH; each POLY is independently a water-soluble, non-peptidic polymer; each Xr is independently a linkage-containing spacer moiety; q is a positive integer from 3 to about 50; and each TLR 7/8 AG is a Toll-like receptor 7/8 agonist.

Abstract: Provided are multi-arm polymer conjugates of Toll-Like Receptor (“TLR”) agonists such as TLR 7/8 agonists, as well as related compositions, and methods of making and using such conjugates. Exemplary conjugates are encompassed by Formula I: (I) or a pharmaceutically acceptable salt form thereof, where R, taken together with each Q, is a residue of a polyol, polythiol, or polyamine bearing from 3 to about 50 hydroxyl, thiol, or amino groups; each Q is a linker selected from oxygen, sulfur and —NH; each POLY is independently a water-soluble, non-peptidic polymer; each Xr is independently a linkage-containing spacer moiety; q is a positive integer from 3 to about 50; and each TLR 7/8 AG is a Toll-like receptor 7/8 agonist. Also provided is a method of administering to a patient having cancer (a) an IL-2R?-activating amount of a long-acting, IL-2R?-selective agonist; and (b) a Toll-like receptor agonist such as a conjugate as described above, as well as related compositions, kits and methods.

Abstract: This disclosure provides methods for treating a tumor in a subject comprising administering to the subject an anti-PD-1 antibody and a CD-122-biased agonist. In some embodiments, the tumor is derived from a melanoma, a renal cell carcinoma (RCC), a non-small cell lung carcinoma (NSCLC), a urothelial cancer (UC), a breast cancer, or any combination thereof.

Abstract: The instant disclosure provides selective Treg stimulator compositions, including RUR20kD-IL-2 and related compositions, and methods of using these compositions, for example, for treating autoimmune diseases, and/or other conditions responsive to therapy that is effective to provide a selective increase in numbers and activation of regulatory T cells over effector T cells.

Abstract: Provided herein are methods and compositions for treating a subject having cancer by administering to the subject a neoantigen-based vaccine composition and a long acting, IL-2RP?-selective agonist composition comprised of compounds of Formula (I), and optionally, an anti-PD-1 antibody.

Abstract: Disclosed herein are methods in the field of cancer immunotherapy that involve the treatment of a subject having cancer by administering to the subject a toll-like receptor 7/8 (TLR7/8) agonist in combination with a long-acting IL-2R?-biased agonist and a programmed cell death protein 1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) axis inhibitor, and related compositions, dosage forms, and kits.

Abstract: Provided are multi-arm polymer conjugates of Toll-Like Receptor (“TLR”) agonists such as TLR 7/8 agonists, as well as related compositions, and methods of making and using such conjugates. Exemplary conjugates are encompassed by Formula I: (I) or a pharmaceutically acceptable salt form thereof, where R, taken together with each Q, is a residue of a polyol, polythiol, or polyamine bearing from 3 to about 50 hydroxyl, thiol, or amino groups; each Q is a linker selected from oxygen, sulfur and —NH; each POLY is independently a water-soluble, non-peptidic polymer; each Xr is independently a linkage-containing spacer moiety; q is a positive integer from 3 to about 50; and each TLR 7/8 AG is a Toll-like receptor 7/8 agonist. Also provided is a method of administering to a patient having cancer (a) an IL-2R?-activating amount of a long-acting, IL-2R?-selective agonist; and (b) a Toll-like receptor agonist such as a conjugate as described above, as well as related compositions, kits and methods.

Abstract: Provided herein are combination methods and compositions for cancer therapies. The combinations modify multiple arms of the immune system, including an innate immunity modifier, an immune checkpoint inhibitor and a T-cell stimulator, to treat cancer.

Abstract: Provided herein are methods and compositions for treating a subject having cancer by administering to the subject a cancer vaccine accompanied by administration of a long acting IL-2R??-biased agonist.

Abstract: The invention relates to a pharmaceutical composition comprising a variant TNF-? protein that inhibits the activity of soluble TNF-? while substantially maintaining the activity of transmembrane TNF-?, a buffer, and a tonicity agent, wherein said composition has a pH from approximately 5.0 to 8.0.

Abstract: A method of treating a mammal with an adiponectin mediated disorder comprising administering a therapeutically effective amount of an adiponectin variant with at least a 3-fold increased solubility relative to residues 110-244 of human adiponectin.

Abstract: An adiponectin variant with one or more amino acid modifications relative to a corresponding parent adiponectin, wherein the solubility of the variant is improved by at least 3-fold relative to residues 110-244 of human adiponectin.

Abstract: The invention relates to novel proteins with TNF-alpha antagonist activity and nucleic acids encoding these proteins. The invention further relates to the use of the novel proteins in the treatment of TNF-alpha related disorders.

Abstract: A composition comprising an adiponectin variant at a concentration of at least 2.0 mg/mL, and a pharmaceutically acceptable carrier, wherein less than 20% of said adiponectin variant would aggregate after storage at 4° C. for one week in 10 mM PO4, 150 mM NaCl buffer.

Abstract: The invention relates to a pharmaceutical composition comprising a variant TNF-? protein that inhibits the activity of soluble TNF-? while substantially maintaining the activity of transmembrane TNF-? a buffer and a tonicity agent wherein said composition has a pH from approximately 5.0 to 8.0.

Abstract: The present invention relates to the use of simulation technology to rationally optimize the locations and sizes of attached polymeric moieties for modification of therapeutic proteins and the proteins generated from this method.

Abstract: The present invention relates to the use of simulation technology to rationally optimize the locations and sizes of attached polymeric moieties for modification of therapeutic proteins and the proteins generated from this method.

Abstract: An adiponectin variant with one or more amino acid modifications relative to a corresponding parent adiponectin, wherein the adiponectin variant is not glycosylated, the adiponectin variant does not have residues 1-100 relative to human adiponectin, and wherein the solubility of the variant is improved by at least 3-fold relative to residues 110-244 of human adiponectin.

Abstract: The present invention relates to the use of simulation technology to rationally optimize the locations and sizes of attached polymeric moieties for modification of therapeutic proteins and the proteins generated from this method.